Open AccessA pharmacogenetic pilot study of CYP2C9 common genetic variant and sulfonylureas therapeutic response in type 2 diabetes mellitus patients
Author(s) -
Elham Didari,
Negar Sarhangi,
Mahdi Afshari,
Hamid Reza Aghaei Meybodi,
Mandana Hasanzad
Publication year - 2021
Publication title -
journal of diabetes and metabolic disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.619
H-Index - 33
ISSN - 2251-6581
DOI - 10.1007/s40200-021-00894-0
Subject(s) - cyp2c9 , medicine , type 2 diabetes mellitus , glycemic , genotyping , pharmacogenetics , sulfonylurea , pharmacology , diabetes mellitus , gastroenterology , blood sugar , endocrinology , insulin , genotype , biology , cytochrome p450 , gene , genetics , metabolism
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease that is associated with elevated blood glucose levels. Sulfonylureas (SFUs) are the most widely used among the oral antidiabetic drugs that are highly metabolized by cytochrome P450 family 2 subfamily C member 9 (CYP2C9). The CYP2C9 has been shown to be associated with a better glycemic response to SFUs and a lower treatment failure rate. The aim of the present study was to assess the influence of the CYP2C9 rs1067910 gene variant on the SFUs response in a group of Iranian patients for the first time.